TASP0415914
Modify Date: 2025-08-31 12:03:45
TASP0415914 structure
|
Common Name | TASP0415914 | ||
|---|---|---|---|---|
| CAS Number | 1292300-75-4 | Molecular Weight | 323.37100 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C13H17N5O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TASP0415914TASP0415914 is a potent and orally active PI3Kγ inhibitor with an IC50 of 29 nM. TASP0415914 also shows potent Akt inhibitory activities with an IC50 of 294 nM. TASP0415914 can be used for inflammatory diseases research[1]. |
| Name | N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide |
|---|
| Description | TASP0415914 is a potent and orally active PI3Kγ inhibitor with an IC50 of 29 nM. TASP0415914 also shows potent Akt inhibitory activities with an IC50 of 294 nM. TASP0415914 can be used for inflammatory diseases research[1]. |
|---|---|
| Related Catalog | |
| Target |
PI3Kγ:29 nM (IC50) Akt:294 nM (IC50) |
| In Vitro | TASP0415914 (compound 8j) shows high metabolic stability in rat/human liver microsomes. TASP0415914 has no CYP inhibition up to 10 μM for CYP1A2, 2C9, 2C19, 2D6 and 3A4[1]. |
| In Vivo | TASP0415914 (compound 8j; 10-100 mg/kg; orally administration; twice daily; for 14 days) treatment suppressed the progression of the disease in a dose-dependent manner in a mouse collagen-induced arthritis (CIA) model[1]. Animal Model: Collagen-primed DBA/1 mice[1] Dosage: 10 mg/kg; 30 mg/kg; 100 mg/kg Administration: Orally administration; twice daily; for 14 days Result: Suppressed the progression of the disease in a dose-dependent manner. |
| References |
| Molecular Formula | C13H17N5O3S |
|---|---|
| Molecular Weight | 323.37100 |
| Exact Mass | 323.10500 |
| PSA | 132.62000 |
| LogP | 1.55900 |
| InChIKey | WFQFHKQIDOCQTL-UHFFFAOYSA-N |
| SMILES | CC(=O)Nc1nc(C)c(-c2nc(N3CCCC(O)C3)no2)s1 |
| Hazard Codes | Xi |
|---|
Total 39, Current Page 1 of 4
1
2
3
4